Sai Priya Anand
Overview
Explore the profile of Sai Priya Anand including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
1377
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Anand S, Tam C, Calvin S, Ayache D, Slywchuk L, Lambraki I, et al.
Can Commun Dis Rep
. 2024 Sep;
50(9):282-293.
PMID: 39257839
Background: The COVID-19 pandemic highlighted the need for timely, evidence-based rapid risk assessments (RRA) of infectious disease events to inform public health action during rapidly evolving situations with high uncertainty....
2.
Marchitto L, Richard J, Prevost J, Tauzin A, Yang D, Chiu T, et al.
J Virol
. 2024 Sep;
98(10):e0101624.
PMID: 39248460
The majority of naturally elicited antibodies against the HIV-1 envelope glycoproteins (Env) are non-neutralizing (nnAbs) because they are unable to recognize the Env trimer in its native "closed" conformation. Nevertheless,...
3.
Marchitto L, Richard J, Prevost J, Tauzin A, Yang D, Chiu T, et al.
bioRxiv
. 2024 Jun;
PMID: 38895270
The majority of naturally-elicited antibodies against the HIV-1 envelope glycoproteins (Env) are non-neutralizing (nnAbs), because they are unable to recognize the Env timer in its native "closed" conformation. Nevertheless, it...
4.
Brunet-Ratnasingham E, Morin S, Randolph H, Labrecque M, Belair J, Lima-Barbosa R, et al.
Nat Commun
. 2024 May;
15(1):4177.
PMID: 38755196
Plasma RNAemia, delayed antibody responses and inflammation predict COVID-19 outcomes, but the mechanisms underlying these immunovirological patterns are poorly understood. We profile 782 longitudinal plasma samples from 318 hospitalized patients...
5.
Chen Y, Prevost J, Ullah I, Romero H, Lisi V, Tolbert W, et al.
iScience
. 2022 Dec;
26(1):105783.
PMID: 36514310
Neutralizing antibodies (NAbs) hold great promise for clinical interventions against SARS-CoV-2 variants of concern (VOCs). Understanding NAb epitope-dependent antiviral mechanisms is crucial for developing vaccines and therapeutics against VOCs. Here...
6.
Prevost J, Anand S, Rajashekar J, Zhu L, Richard J, Goyette G, et al.
Cell Rep
. 2022 Nov;
41(6):111624.
PMID: 36351384
Non-neutralizing antibodies (nnAbs) can eliminate HIV-1-infected cells via antibody-dependent cellular cytotoxicity (ADCC) and were identified as a correlate of protection in the RV144 vaccine trial. Fc-mediated effector functions of nnAbs...
7.
Chen Y, Sun L, Ullah I, Beaudoin-Bussieres G, Anand S, Hederman A, et al.
Sci Adv
. 2022 Jul;
8(28):eabn4188.
PMID: 35857504
Soluble angiotensin-converting enzyme 2 (ACE2) constitutes an attractive antiviral capable of targeting a wide range of coronaviruses using ACE2 as their receptor. Using structure-guided approaches, we developed a series of...
8.
Valcourt E, Manguiat K, Robinson A, Lin Y, Abe K, Mubarek S, et al.
Microbiol Spectr
. 2022 Jun;
10(4):e0055322.
PMID: 35730975
No abstract available.
9.
Boutin M, Vezina D, Ding S, Prevost J, Laumaea A, Marchitto L, et al.
mBio
. 2022 Apr;
13(3):e0057722.
PMID: 35475646
The heavily glycosylated HIV-1 envelope glycoprotein (Env) is the sole viral antigen present at the surface of virions and infected cells, representing the main target for antibody responses. The FDA-approved...
10.
Tauzin A, Gendron-Lepage G, Nayrac M, Anand S, Bourassa C, Medjahed H, et al.
Viruses
. 2022 Mar;
14(3).
PMID: 35336940
SARS-CoV-2 infection rapidly elicits anti-Spike antibodies whose quantity in plasma gradually declines upon resolution of symptoms. This decline is part of the evolution of an immune response leading to B...